Vertex Looks To Triple Combos For CF After Doublet Success

Top-line results from two Phase III studies indicate Vertex’s potential new combination cystic fibrosis therapy, tezacaftor plus ivacaftor, is effective and well tolerated in certain cystic fibrosis patients, and could become the backbone of a triple combination therapy for a wider patient group.

Cystic fibrosis word cloud

Vertex Pharmaceuticals Inc. announced positive top-line results from two Phase III studies, EVOLVE and EXPAND, of its investigational cystic fibrosis therapy, tezacaftor (VX-661)/ivacaftor in the evening of March 28, in two patient subgroups, and suggested the double combination could become an important base therapy in the company’s efforts to develop a triple combination that is clinically beneficial in a higher proportion of CF patients.

“Our long-term goal is to make combination therapies available to fundamentally alter the progression of cystic fibrosis in all patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D